

Present Value of Toviaz Worldwide Sales

| Year | Worldwide Sales [A] | Inflation Adjustment | | Present Value Factor | | Present Value of Worldwide Sales | |
|-------|------------------------|----------------------|-------------|----------------------|-------------|----------------------------------|-------------|
| | | 1998 [B] | 2008 [C] | 1998 [D] | 2008 [E] | 1998 [F] | 2008 [G] |
| 2009 | \$ 59.0 | 0.760 | 1.004 | 0.313 | 0.890 | \$ 14.0 | \$ 52.7 |
| 2010 | \$ 137.0 | 0.748 | 0.987 | 0.283 | 0.805 | \$ 29.0 | \$ 108.9 |
| 2011 | \$ 187.0 | 0.725 | 0.957 | 0.256 | 0.729 | \$ 34.7 | \$ 130.4 |
| 2012 | \$ 207.0 | 0.710 | 0.938 | 0.232 | 0.659 | \$ 34.1 | \$ 128.0 |
| 2013 | \$ 236.0 | 0.700 | 0.924 | 0.210 | 0.597 | \$ 34.7 | \$ 130.2 |
| 2014 | \$ 288.0 | 0.689 | 0.909 | 0.190 | 0.540 | \$ 37.7 | \$ 141.5 |
| Total | \$ 1,114.0 | n/a | n/a | n/a | n/a | \$ 184.2 | \$ 691.7 |

Notes and sources:

Monetary values are in millions of \$U.S.

[A] Nominal worldwide sales figures are from Exhibit 1036.

[B] to [C] = 1 / (CPI for specified year (row) / CPI for specified year (column)) from Exhibit 1049.

[D] to [E] Calculated from month and day of Toviaz approval (October 31) for 2008 and patent priority (May 12) for 1998.

The discount rate used is 10.5% based on:

Grabowski, Henry and Ronald Hansen, "Briefing Cost of Developing a New Drug," Tufts Center for the Study of Drug Development, 11/18/2014, at 20.

[F] = [A] x [B] x [D].

[G] = [A] x [C] x [E].